Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04849052 · ClinicalTrials.gov registry record · Phase 1
Text Messaging to Increase Activity in Midlife
A Phase 1 study of Middle Aged, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT04849052 is a Phase 1 study of Middle Aged that has completed, run by Massachusetts General Hospital. The registered enrollment target is 116 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04849052, a Phase 1 study of Middle Aged, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized controlled pilot trial of a text message intervention to promote physical activity in midlife adults (MASTERY), compared to an attention-matched control condition. The MASTERY intervention utilizes two-way text message sessions once-weekly for 12 weeks focusing on performing activities to enhance well being, setting physical activity goals, and learning techniques to reduce midlife-specific stress.
Conditions Studied
Interventions
- BEHAVIORAL MASTERY
- BEHAVIORAL Attentional Control
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2024-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04849052
The ClinicalTrials.gov registry entry for NCT04849052 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Middle Aged appearing as the primary indexed condition, and to 2 interventions - of which MASTERY is the first listed.
NCT04849052 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04849052 about?
NCT04849052 is a clinical study titled "Text Messaging to Increase Activity in Midlife". This is a randomized controlled pilot trial of a text message intervention to promote physical activity in midlife adults (MASTERY), compared to an attention-matched control condition. The MASTERY intervention utilizes two-way text message sessions once-weekly for 12 weeks focusing on performing act...
What is the current status of trial NCT04849052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2021-09-16. Estimated completion is 2024-09-16.
What conditions does trial NCT04849052 study?
This clinical trial studies the following conditions: Middle Aged.
What interventions are being tested in trial NCT04849052?
The interventions under investigation include: MASTERY (BEHAVIORAL), Attentional Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT04849052?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04849052 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Middle Aged
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.